Hello Everyone, We are excited to announce that ResearchDx will be attending ASCO 2023! We will be exhibiting at booth # 13029 from June 3-5. Come stop by to learn how we can help your company expand and incentivise its companion diagnostics pipeline.
Abreos Biosciences Announces Partnership with CLIA/CAP Certified Laboratory, ResearchDx
Commercial assay for Tysabri (Natalizumab) developed to enable physicians to make data driven decisions on how to optimize the infusion schedule for their multiple sclerosis patients. SAN DIEGO, Calif. (PRWEB) August 30, 2018 — Abreos Biosciences, a leader in the precision dosing of biological therapeutics, is pleased to announce a collaboration with ResearchDx, a recognized […]
ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers
Irvine, CA—October 2, 2017—ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and […]
ResearchDx And BioSmartSA Announce New Consulting Practice in Saudi Arabia
Irvine, California and Riyadh, Saudi Arabia, May 17, 2016 — ResearchDx, the premier Contract Diagnostics Organization (CDO) for the biopharmaceutical industry, and BioSmartSA, a healthcare consultancy based in Saudi Arabia, have formed a partnership to bring their expertise in navigating the design and management of diagnostic services to healthcare providers in the Kingdom of Saudi Arabia […]
ResearchDx/PacificDx to Present High-Resolution HER2 Testing Data at the San Antonio Breast Cancer Symposium
Leading contract diagnostics organization demonstrates the value of DNA-based testing for identifying the HER2-Low genomic subtype in high-risk HER2 equivocal breast cancer Irvine, CA—December 1, 2016—ResearchDx/PacificDx announced today that it will share findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in breast cancer patients at this year’s San […]
ResearchDx Appointment of New Chief Medical Officer
Irvine, CA—December 7, 2015—Internationally recognized as the “Contract Diagnostics Organization,” ResearchDx specializes in the development of companion and in vitro diagnostics for the pharmaceutical, biotechnology, research, and diagnostic industries. To meet the demand for leveraging new technology and increase the speed at which new treatments reach patients, life sciences firm ResearchDx has appointed Shelly Gunn […]
Irvine’s ResearchDx Signs Agreement with Micron, Inc. of Tokyo
Irvine, CA—February 14, 2015—ResearchDx, Inc. of Irvine, California and Micron Inc. of Tokyo, Japan have entered into an agreement for international collaborative clinical trials. The in vitro diagnostic development processes, laboratory and clinical services of ResearchDx will partner well with Micron’s imaging technologies. Through the collaboration, companies in the U.S., Canada, the European Union, Central […]